NovoCure Limited (NASDAQ:NVCR) Receives $21.20 Average PT from Brokerages

Posted by Francis Steltz on Sep 2nd, 2026

Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have received an average rating of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $21.20.

NVCR has been the topic of several recent research reports. Zacks Research raised NovoCure from a “strong sell” rating to a “hold” rating in a report on Friday, July 24th. Weiss Ratings restated a “sell (d-)” rating on shares of NovoCure in a research report on Thursday, August 27th. Wedbush lifted their price objective on NovoCure from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, July 24th. HC Wainwright set a $32.00 target price on NovoCure in a report on Friday, July 24th. Finally, JPMorgan Chase & Co. initiated coverage on shares of NovoCure in a research report on Monday, July 13th. They set a “neutral” rating and a $17.00 target price for the company.

Get Our Latest Research Report on NVCR

Insiders Place Their Bets

In other news, CEO Frank X. Leonard sold 34,273 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $17.93, for a total value of $614,514.89. Following the transaction, the chief executive officer directly owned 459,520 shares of the company’s stock, valued at $8,239,193.60. The trade was a 6.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.55% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in NovoCure by 4.8% during the 4th quarter. Vanguard Group Inc. now owns 10,958,209 shares of the medical equipment provider’s stock worth $141,690,000 after purchasing an additional 502,368 shares in the last quarter. Sei Investments Co. grew its position in NovoCure by 367.6% during the first quarter. Sei Investments Co. now owns 114,281 shares of the medical equipment provider’s stock valued at $1,246,000 after buying an additional 89,839 shares during the period. Eversept Partners LP purchased a new stake in NovoCure during the fourth quarter worth about $1,564,000. First Trust Advisors LP bought a new stake in NovoCure in the first quarter worth about $1,028,000. Finally, Quantinno Capital Management LP boosted its stake in NovoCure by 23.7% in the first quarter. Quantinno Capital Management LP now owns 2,487,376 shares of the medical equipment provider’s stock valued at $27,112,000 after acquiring an additional 477,128 shares during the last quarter. 84.61% of the stock is owned by institutional investors.

NovoCure Stock Performance

NVCR opened at $17.38 on Friday. The firm has a market cap of $2.02 billion, a P/E ratio of -13.37 and a beta of 1.01. NovoCure has a 52-week low of $9.82 and a 52-week high of $21.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.70 and a current ratio of 2.89. The business’s fifty day moving average is $16.67 and its 200-day moving average is $14.92.

NovoCure (NASDAQ:NVCR – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical equipment provider reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.20. NovoCure had a negative net margin of 21.25% and a negative return on equity of 44.00%. The business had revenue of $183.58 million during the quarter, compared to the consensus estimate of $172.44 million. During the same period in the previous year, the business earned ($0.36) earnings per share. The company’s revenue was up 15.6% on a year-over-year basis. Sell-side analysts expect that NovoCure will post -1.21 EPS for the current fiscal year.

NovoCure Company Profile

(Get Free Report)

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.